Entering text into the input field will update the search result below

AKTX Akari Therapeutics, Plc
Stock Price & Overview

$3.17-0.16 (-4.80%)1:22 PM 12/06/23
NASDAQ | $USD | Delayed


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

People Also Follow

Company Profile

Akari Therapeutics, Plc logo
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
  • 75/76 Wimpole Street
  • London, W1G 9RT
  • United Kingdom
Phone Number
44 20 8004 0270
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.